San Francisco, California, August 12, 2026
Tasman Therapeutics announced a multi-year strategic partnership with Osmind to support the development of R-107, an investigational extended-release oral ketamine product being developed for treatment-resistant depression (TRD) and other difficult-to-treat depressive disorders. The collaboration will combine Osmind’s real-world evidence platform, artificial intelligence capabilities, electronic health record technology, and national network of psychiatry practices with Tasman’s clinical development program. The partnership is designed to support Tasman’s pivotal Phase 3 ROCKET program, strengthen regulatory and clinical execution, and establish a technology- and data-enabled framework for the potential future commercialization of R-107.
Osmind Data to Support Phase 3 Development
Under the partnership, Tasman plans to leverage Osmind’s real-world data and clinical network to support the design and execution of the ROCKET Phase 3 program. The collaboration is expected to contribute to trial design optimization, safety characterization, regulatory strategy, clinical trial site identification, and awareness initiatives across Osmind’s network of interventional psychiatry practices. Osmind operates a large U.S. network of independent psychiatry practices providing next-generation treatments for treatment-resistant depression, including intravenous ketamine and intranasal esketamine. Its psychiatry-focused electronic health record and artificial intelligence platform provides access to a substantial real-world dataset involving patients treated with rapid-acting psychopharmacologic therapies. This infrastructure is intended to help Tasman generate additional evidence and improve the operational execution of its late-stage clinical program.
R-107 Advances as an At-Home Ketamine Treatment
R-107 is an investigational Phase 3 extended-release oral ketamine tablet being developed as a monotherapy for treatment-resistant depression. Unlike conventional ketamine administration approaches, Tasman is developing R-107 for at-home administration, with the goal of providing a differentiated treatment option for patients with difficult-to-treat depressive disorders. The candidate has been evaluated in clinical studies and long-term open-label safety trials in Australia and New Zealand since 2021. According to Tasman, its BEDROC Phase 2 study, published in Nature Medicine, demonstrated rapid onset and durable, statistically significant improvements in treatment-resistant depression symptoms compared with placebo, alongside a tolerability profile intended to support self-administration at home. The company’s pivotal Phase 3 ROCKET program is underway, with topline results anticipated in 2027.
Advertisement
Real-World Evidence Supports Future Commercialization
Beyond clinical development, the partnership is intended to establish infrastructure that could support R-107 commercialization and patient care if the therapy receives regulatory approval. Osmind plans to provide technology-enabled capabilities focused on longitudinal evidence generation, a consumer-facing patient application, a longitudinal data registry, and a clinician network model supporting both in-person and at-home care. These capabilities could allow Tasman to use real-world evidence and artificial intelligence to inform patient care, treatment monitoring, compliance, and future evidence generation. The collaboration reflects the increasing role of digital health infrastructure and real-world data in pharmaceutical development, particularly in areas such as psychiatry where treatment response, safety, adherence, and long-term outcomes can benefit from continuous data collection. The partnership represents a significant development milestone for Tasman Therapeutics’ R-107 program as the company advances toward Phase 3 clinical readout. By combining a late-stage investigational therapy with Osmind’s clinical network, real-world evidence, data technology, and AI capabilities, the companies aim to strengthen both the clinical development pathway and potential launch infrastructure for R-107. If successful in Phase 3 and subsequent regulatory review, R-107 could potentially offer patients with treatment-resistant depression an oral, extended-release, at-home treatment option, although its safety and efficacy remain under clinical investigation.
Source: Tasman Therapeutics press release
